Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vercirnon

Next Previous
Drug Profile

Vercirnon

Alternative Names: CCX-282; CCX-282B; GSK'786; GSK-1605786; GSK-1605786-A; Traficet-EN

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ChemoCentryx
  • Developer ChemoCentryx; GlaxoSmithKline
  • Class Anti-inflammatories; Small molecules; Sulfonamides
  • Mechanism of Action CCR9 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Crohn's disease; Ulcerative colitis
  • No development reported Coeliac disease

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 20 Oct 2014 Efficacy and adverse events data from the phase III SHIELD-4 trial in Crohn's disease presented at the 79th Annual Scientific Meeting of the American College of Gastroenterology (ACG-2014)
  • 19 May 2014 Vercirnon is available for licensing as of 19 May 2014. http://www.chemocentryx.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top